Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine

Biochemistry

Volumn 45, Issue 11, 2006, Pages 3733-3739

  Chefalo, Peter ^b   Pan, Yanbin ^b   Nagy, Nancy ^b   Guo, Zhongwu ^a,b   Harding, Clifford V ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; CARBOHYDRATES; IMMUNIZATION; METABOLISM; SYNTHESIS (CHEMICAL); TUMORS; VACCINES;

CANCER VACCINES; IMMUNOTHERAPEUTIC STRATEGY; METABOLIC ENGINEERING; TUMOR CELLS;

CELL CULTURE;

ANTISERUM; CANCER VACCINE; GANGLIOSIDE GM3; MANNOSAMINE; MONOSACCHARIDE; N BUTANOYL DEXTRO MANNOSAMINE; N ISOBUTANOYL DEXTRO MANNOSAMINE; N PHENYLACETYL DEXTRO MANNOSAMINE; N PROPIONYL DEXTRO MANNOSAMINE; SIALIC ACID; TUMOR ANTIGEN; TUMOR ASSOCIATED CARBOHYDRATE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BIOENGINEERING; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MELANOMA; METABOLIC ENGINEERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOCHEMISTRY; CANCER VACCINES; CARBOHYDRATE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G(M3) GANGLIOSIDE; GLYCOCONJUGATES; HEXOSAMINES; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; N-ACETYLNEURAMINIC ACID; TIME FACTORS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 33645223459     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi052161r     Document Type: Article

References (59)

1. Schauer, R. (2004) Sialic acids: Fascinating sugars in higher animals and man, Zoology 107, 49-64.
2. Crocker, P. R. (2002) Siglecs: Sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signaling, Curr. Opin. Struct. Biol. 12, 609-615.
3. Crocker, P. R., and Varki, A. (2001) Siglecs in the immune system, Immunology 103, 137-145.
4. Varki, A. (1997) Sialic acids as ligands in recognition phenomena, FASEB J. II, 248-255.
5. Reutter, W., Stasche, R., Stehling, P., and Baum, O. (1997) The biology of sialic acids: Insights into their structure, metabolism and function in particular during viral infection, in Glycosciences (Gabius, H.-J., and Gabius, S., Eds.) pp 245-259, Chapman & Hall, Weinheim, Germany.
6. Troy, F. A. (1992) Polysialylation: From bacteria to brain, Glycobiology 2, 5-23.
7. Wagner, M. (1990) Sialic acid-specific lectins, Adv. Lectin Res. 3, 36-82.
8. Schauer, R. (1988) Sialic acids as antigenic determinants of complex carbohydrates, Adv. Exp. Med. Biol. 228, 47-72.
9. Hakomori, S. (1991) Possible functions of tumor-associated carbohydrate antigens, Curr. Opin. Immunol. 3, 646-653.
10. Hakomori, S., and Zhang, Y. (1997) Glycosphingolipid antigens and cancer therapy, Chem. Biol. 3, 97-104.
11. Takano, R., Muchmore, E., and Dennis, J. W. (1994) Sialylation and malignant potential in tumor cell glycosylation mutants, Glycobiology 4, 665-674.
12. Michalides, R., Kwa, B., Springall, D., van Zandwijk, N., Koopman, J., Hilkens, J., and Mooi, W. (1994) NCAM and lung cancer, Int. J. Cancer, Suppl. 8, 34-37.
13. Tong, L., Baskaran, G., Jones, M. B., Rhee, J. K., and Yarema, K. J. (2003) Glycosylation changes as markers for the diagnosis and treatment of human disease, Biotechnol. Genet. Eng. Rev. 20, 199-244.
14. Danishefsky, S. J., and Allen, J. R. (2000) From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines, Angew. Chem., Int. Ed. 39, 837-863.
15. Ragupathi, G. (1998) Carbohydrate antigens as targets for active specific immunotherapy, Cancer Immunol. Immunother. 46, 82-87.
16. Hellstrom, K. E., Gladstone, P., and Hellstrom, I. (1997) Cancer vaccines: Challenges and potential solutions, Mol. Med. Today, 286-290.
17. Ben-Efraim, S. (1999) One hundred years of cancer immunotherapy: A critical appraisal, Tumor Biol. 20, 1-24.
18. Chen, C.-H., and Wu, T.-C. (1998) Experimental vaccine strategies for cancer immunotherapy, J. Biomed. Sci. 5, 231-252.
19. Livingston, P. O. (1992) Construction of cancer vaccines with carbohydrate and protein tumor antigens, Curr. Opin. Immunol. 4, 624-629.
20. Toyokuni, T., and Singhal, A. K. (1995) Synthetic carbohydrate vaccines based on tumor-associated antigens, Chem. Soc. Rev., 231-242.
21. Reisfeld, R. A., and Cheresh, D. A. H. (1987) Human tumor antigens, Adv. Immunol. 40, 323-377.
22. Hirabayashi, Y., Hamaoka, A., Matsumoto, M., Matsubara, T., Tagawa, M., Wakabayashi, S., and Taniguchi, M. (1985) Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma, J. Biol. Chem. 260, 13328-13333.
23. Stipp, D. (1998) Closing in on the cancer vaccines, Fortune 138, 168-176.
24. Livingston, P. O. (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: From the whole melanoma cells to ganglioside-KLH conjugate vaccines, Immunol. Rev. 145, 147-156.
25. Slovin, S. F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W. G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K. O., Livingston, P. O., Danishefsky, S. J., and Scher, H. I. (1999) Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man, Proc. Natl. Acad. Sci. U.S.A. 96, 5710-5715.
26. Longenecker, B. M., Reddish, M., Koganty, R., and MacLean, G. D. (1993) Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus adjuvant, Ann. N.Y. Acad. Sci. 690, 276-291.
27. Bitton, R. J., Guthmann, M. D., Babri, M. R., Carnero, A. J. L., Alonso, D. F., Fainboim, L., and Gomez, D. E. (2002) Cancer vaccines: An update with special focus on ganglioside antigens, Oncol. Rep. 9, 267-276.
28. Krug, L. M., Ragupathi, G., Ng, K. K., Hood, C., Jennings, H. J., Guo, Z., Kris, M. G., Miller, V., Pizzo, B., Tyson, L., Baez, V., and Livingston, P. O. (2004) Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin, Clin. Cancer Res. 10, 916-923.
29. Holmberg, L. A., Oparin, D. V., Gooley, T., Lilleby, K., Bensinger, W., Reddish, M. A., MacLean, G. D., Longenecker, B. M., and Sandmaier, B. M. (2000) Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine, Bone Marrow Transplant. 25, 1233-1241.
30. Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G. M., Troychak, M. J., Boynton, A. L., and Murphy, G. P. (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial, Prostate 40, 125-129.
31. Slovin, S. F., and Scher, H. I. (1999) Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center, Semin. Oncol. 26, 448-454.
32. MacLean, G. D., Miles, D. W., Rubens, R. D., Reddish, M. A., and Longenecker, B. M. (1996) Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide, J. Immunother. Emphasis Tumor Immunol. 19, 309-316.
33. Kuduk, S. D., Schwarz, J. B., Chen, X. T., Glunz, P. W., Sames, D., Ragupathi, G., Livingston, P. O., and Danishefsky, S. J. (1998) Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: The preparation of a glycopeptide-based vaccine for clinical trials against prostate, J. Am. Chem. Soc. 120, 12474-12485.
34. Liu, T., Guo, Z., Yang, Q., Sad, S., and Jennings, H. J. (2000) Biochemical engineering of surface α(2-8)polysialic acid for immunotargeting cancer cells, J. Biol. Chem. 275, 32832-32836.
35. Ritter, G., Boosfeld, E., Calves, M. I., Oettgen, H. F., Old, L. J., and Livingston, P. O. (1990) Antibody response after immunization with ganglioside GD3, GD3 lactones, GD3 amide and GD3 gangliosidol in the mouse. GD3 lactone I induces antibodies reactive with human melanoma, Immunobiology 182, 32.
36. Ritter, G., Boosfeld, E., Asluri, S., Calves, M. I., Oettgen, H. F., Old, L. J., and Livingston, P. O. (1991) Antibody response after immunization with ganglioside GD3, GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma, Int. J. Cancer 48, 379-385.
37. Jennings, H. J., and Sood, R. K. (1994) Synthetic glycoconjugates as human vaccines, in Neoglycoconjugates: Preparation and Applications (Lee, Y. C., and Lee, R. T., Eds.) pp 325-371, Academic Press, San Diego.
38. Pon, R., Lussier, M., Yang, Q., and Jennings, H. J. (1997) N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B neisseria meningitides, J. Exp. Med. 185, 1929-1938.
39. Chefalo, P., Pan, Y. B., Nagy, N., Harding, C. V., and Guo, Z. (2004) Preparation and immunological studies of protein conjugates of N-acylneuraminic Acids, Glycoconjugate J. 20, 407-414.
40. Pan, Y. B., Chefalo, P., Nagy, N., Hording, C. V., and Guo, Z. (2005) Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines, J. Med. Chem. 48, 875-883.
41. Kayser, H., Geile, C. C., Paul, C., Zeitler, R., and Reutter, W. (1992) Incorporation of N-acyl-2-amino-2-deoxy-hexoses into glycosphingolipids of pheochromocytoma cell line PC12, FEBS Lett. 301, 137-140.
42. Schmidt, C., Stehling, P., Schnitzer, J., Reutter, W., and Horskorte, R. (1998) Biological engineering of neural cell surfaces by the synthetic N-propanoyl-substituted neuramimc acid precursor, J. Biol. Chem. 273, 19146-19152.
43. Bertozzi, C. R., and Kiessling, L. L. (2001) Chemical glycobiology, Science 291, 2357-2364.
44. Saxon, E., and Bertozzi, C. R. (2000) Cell surface engineering by a modified Staudinger reaction, Science 287, 2007-2010.
45. Mahal, L. K., and Bertozzi, C. R. (1997) Engineering cell surfaces: Fertile ground for molecular landscaping, Chem. Biol. 4, 415-422.
46. Yarema, K. J., Mahal, L. K., Bruehl, R. E., Rodriguez, E. C., and Bertozzi, C. R. (1998) Metabolic delivery of ketone groups to sialic acid residues. Application to cell surface glycoform engineering, J. Biol. Chem. 273, 31168-31179.
47. Mahal, K. L., Yarema, K. J., and Bertozzi, C. R. (1997) Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis, Science 276, 1125-1128.
48. Keppler, O. T., Stehling, P., Herrmann, M., Kayser, H., Grunow, D., Reutter, W., and Pawlita, M. (1995) Biosynthetic modulation of sialic acid-dependent virus-receptor interactions of two primate polyoma viruses, J. Biol. Chem. 270, 1308-1314.
49. Keppler, O. T., Horstkorte, R., Pawlita, M., Schmidt, C., and Reutter, W. (2001) Biochemical engineering of the N-acyl side chain of sialic acid: Biological implications, Glycobiology 11, 11R-18R.
50. Charter, N. W., Mahal, L. K., Koshland, D. E. J., and Bertozzi, C. R. (2002) Differential effects of unnatural sialic acids on the polysialylation of the neural cell adhesion molecule and neuronal behavior, J. Biol. Chem. 277, 9255-9261.
51. Lemieux, G. A., and Bertozzi, C. R. (2001) Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens, Chem. Biol. 8, 265-275.
52. Luchansky, S. J., Goon, S., and Bertozzi, C. R. (2004) Expanding the diversity of unnatural cell-surface sialic acids, ChemBioChem 5, 371-374.
53. Goon, S., Schilling, B., Tullius, M. V., Gibson, B. W., and Bertozzi, C. R. (2003) Metabolic incorporation of unnatural sialic acids into Haemophilus ducreyi lipooligosaccharides, Proc. Natl. Acad. Sci. U.S.A. 100, 3089-3094.
54. Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., and Muchmore, E. (2003) Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid, Proc. Natl. Acad. Sci. U.S.A. 100, 12045-12050.
55. Zou, W., Borrelli, S., Gilbert, M., Liu, T., Pon, R. A., and Jennings, H. J. (2004) Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells, J. Biol. Chem. 279, 25390-25399.
56. Pan, Y., Ayani, T., Nadas, J., and Guo, Z. (2004) Accessibility of N-acyl derivatives of D-mannosamine to N-acetylneuraminic acid aldolase, Carbohydr. Res. 339, 2091-2100.
57. Jacobs, C. L., Goon, S., Yarema, K. J., Hinderlich, S., Hang, H. C., Chai, D. H., and Bertozzi, C. R. (2001) Substrate specificity of the sialic acid biosynthetic pathway, Biochemistry 40, 12864-12874.
58. Nakamura, M., Kirito, K., Yamanoi, J., Wainai, T., Nojiri, H., and Saito, M. (1991) Ganglioside GM3 can induce megakaryocytoid differentiation of human leukemia cell line K562 cells, Cancer Res. 51, 1940-1945.
59. Mahal, L. K., Charter, N. W., Angata, K., Fukuda, M., Koshland, D. E., and Bertozzi, C. R. (2001) A small-molecule modulator of poly-α-2,8-sialic acid expression on cultured neurons and tumor cells, Science 294, 380-382.